Literature DB >> 23550647

A daunting task: manipulating leukocyte function with RNAi.

Dan Peer1.   

Abstract

RNA interference (RNAi) has advanced into clinical trials. In spite of the progress made in systemic RNAi delivery to the liver and solid tumors, delivery of RNAi to leukocytes remains challenging and less advanced. Manipulating leukocyte function with RNAi holds great promise for streamlining the drug discovery process by facilitating in vivo drug target validation and for facilitating the development of RNAi-based therapy platforms for leukocyte-implicated diseases, such as blood cancer, inflammation, and leukocyte-tropic viral infections. In this review, progress in delivery strategies of RNAi payloads to leukocytes, which are notoriously difficult cells to transduce with RNAi, is discussed with special emphasis on the challenges and potential opportunities for manipulating leukocyte function with RNAi.
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23550647     DOI: 10.1111/imr.12044

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  18 in total

Review 1.  In vitro and ex vivo strategies for intracellular delivery.

Authors:  Martin P Stewart; Armon Sharei; Xiaoyun Ding; Gaurav Sahay; Robert Langer; Klavs F Jensen
Journal:  Nature       Date:  2016-10-13       Impact factor: 49.962

Review 2.  Manipulating the in vivo immune response by targeted gene knockdown.

Authors:  Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2015-07-03       Impact factor: 7.486

3.  Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.

Authors:  Shiri Weinstein; Itai A Toker; Rafi Emmanuel; Srinivas Ramishetti; Inbal Hazan-Halevy; Daniel Rosenblum; Meir Goldsmith; Avigdor Abraham; Ohad Benjamini; Osnat Bairey; Pia Raanani; Arnon Nagler; Judy Lieberman; Dan Peer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-23       Impact factor: 11.205

Review 4.  MicroRNA-mediated regulation of T helper cell differentiation and plasticity.

Authors:  Dirk Baumjohann; K Mark Ansel
Journal:  Nat Rev Immunol       Date:  2013-08-02       Impact factor: 53.106

5.  Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.

Authors:  Anugraha Rajagopalan; Alexey Berezhnoy; Brett Schrand; Yvonne Puplampu-Dove; Eli Gilboa
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

Review 6.  Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes.

Authors:  Shoshy Mizrahy; Inbal Hazan-Halevy; Niels Dammes; Dalit Landesman-Milo; Dan Peer
Journal:  Mol Ther       Date:  2017-04-06       Impact factor: 11.454

Review 7.  Modulation of Immune Response Using Engineered Nanoparticle Surfaces.

Authors:  Daniel F Moyano; Yuanchang Liu; Dan Peer; Vincent M Rotello
Journal:  Small       Date:  2015-11-30       Impact factor: 13.281

8.  RNA regulation of the immune system.

Authors:  K Mark Ansel
Journal:  Immunol Rev       Date:  2013-05       Impact factor: 12.988

9.  Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition.

Authors:  Yvonne Puplampu-Dove; Tal Gefen; Anugraha Rajagopalan; Darija Muheramagic; Brett Schrand; Eli Gilboa
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 10.  Targeting microRNAs for immunomodulation.

Authors:  Lukas T Jeker; Romina Marone
Journal:  Curr Opin Pharmacol       Date:  2015-05-25       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.